StockData
Vaccinex, Inc. logo

Vaccinex, Inc. (VCNX) stock

VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)

Close on Oct 19, 2026Market cap $3.22MP/E –Yield –

Vaccinex ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Vaccinex's ebitda for the twelve months ending Dec 31, 2019 was -$31.77M. For fiscal 2019 it was -$31.77M.

Annual ebitda

PeriodPeriod endValueChange
FY2019Dec 31, 2019-$31.77M–
FY2018Dec 31, 2018-$27.06M–
FY2017Dec 31, 2017-$20.90M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2019Dec 31, 2019-$6.27M–
Q3 FY2019Sep 30, 2019-$7.61M–
Q2 FY2019Jun 30, 2019-$8.80M–
Q1 FY2019Mar 31, 2019-$9.08M–
Q4 FY2018Dec 31, 2018-$8.50M–
Q3 FY2018Sep 30, 2018-$6.40M–
Q2 FY2018Jun 30, 2018-$6.50M-114.3%
Q1 FY2018Mar 31, 2018-$5.65M–
Q4 FY2017Dec 31, 2017-$6.14M–
Q3 FY2017Sep 30, 2017-$5.28M–
Q2 FY2017Jun 30, 2017$45.33M–

More Vaccinex figures

See a number that looks wrong?